Aranesp® (darbepoetin alfa) |
||
| Aranesp® is used for the treatment of anaemia associated with chronic renal failure, or resulting from concomitantly administered chemotherapy when treating a non-myeloid malignancy .
|
||
Neulasta® (pegfilgrastim) |
||
| A long acting leukocyte growth factor used to decrease the duration of severe neutropenia and incidence of infection in patients with cancer.
|
||
NEUPOGEN® (Filgrastim) |
||
| A leukocyte growth factor used to decrease the duration of neutropenia and incidence of infection in patients with cancer, and for use in patients with severe chronic neutropenia and HIV patients with neutropenia. It is also used in mobilisation of peripheral blood progenitor cells.
|
||
Nplate® (romiplostim) |
||
| A thrombopoietin mimetic used to treat low blood platelet counts in adults with chronic immune thrombocytopenic purpura (ITP).
|
||
Prolia® (denosumab) |
||
| Prolia® is indicated for the treatment of osteoporosis in postmenopausal women. Prolia® significantly reduces the risk of vertebral, non-vertebral and hip fractures.
|
||
Sensipar® (cinacalcet HCl) |
||
| Sensipar is used for the treatment of secondary hyperparathyroidism in dialysis patients with end stage renal disease, hypercalcaemia in patients with parathyroid carcinoma and primary hyperparathyroidism in patients for whom parathyroidectomy is not an option.
|
||
Vectibix® (panitumumab) |
||
| An EGFR inhibitor used to treat colorectal cancer that has spread to other parts of the body after failure of chemotherapy.
|
||
XGEVA® (denosumab) |
||
| XGEVA is indicated for the prevention of skeletal related events in patients with bone metastases from solid tumours
|
||
Total of 8 Products |
